gip glp 1 receptor agonist drugs GIPR/GLP-1R dual therapies for diabetes and weight loss—chemistry, physiology, and clinical applications Indications for GLP-1/GIP RA Summary
Description
Across studies, fat mass decline predominated, whereas reductions in lean body mass were modest
Future research should focus on elucidating the complex mechanisms underlying their psychological effects and integrating mental health considerations into therapeutic strategies
Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials
Most Americans about 92% have health insurance, either at work, through Medicare or Medicaid, or an individual Affordable Care Act (ACA) plan
